

Can't find or afford Effient? Learn about alternatives like Clopidogrel (Plavix) and Ticagrelor (Brilinta) that your doctor may consider as a replacement.
If you've been prescribed Effient (Prasugrel) and you're having trouble finding it at your pharmacy — or the cost is too high — you may be wondering whether there are alternatives. The short answer is yes, there are other antiplatelet medications that work similarly. But switching is not something you should do on your own.
In this article, we'll explain what Effient does, how it works, and walk you through the main alternatives your doctor might consider. We'll also explain the key differences so you can have an informed conversation with your cardiologist.
Important: Never stop taking Effient or switch to a different medication without talking to your doctor first. If you have a stent, stopping antiplatelet therapy can cause life-threatening stent thrombosis.
Effient is the brand name for Prasugrel, an antiplatelet medication. It's prescribed to patients with acute coronary syndromes (ACS) — conditions like heart attack or unstable angina — who are being treated with a stent procedure (percutaneous coronary intervention, or PCI).
After a stent is placed in a blocked artery, there's a risk that blood clots can form on the stent itself. This is called stent thrombosis, and it can be fatal. Effient helps prevent this by keeping your platelets from clumping together.
For a detailed explanation, see our article on how Effient works.
Effient is a thienopyridine P2Y12 inhibitor. Here's what that means in plain language:
Effient is a prodrug, meaning your body has to convert it into its active form before it works. It's taken as a one-time 60 mg loading dose, then 10 mg once daily (or 5 mg for patients under 60 kg), always alongside aspirin.
If you can't fill your Effient prescription — whether due to availability, cost, or a medical reason — here are the main alternatives your doctor may consider:
Clopidogrel is the most widely prescribed P2Y12 inhibitor and the most common alternative to Effient. Like Prasugrel, it's a thienopyridine prodrug that irreversibly blocks the P2Y12 receptor.
Key differences from Effient:
Clopidogrel is often the default antiplatelet for patients with ACS and is sometimes required by insurance plans before they'll cover Effient (a process called step therapy).
Ticagrelor is a newer antiplatelet that works differently from both Effient and Clopidogrel. Instead of irreversibly blocking P2Y12, Ticagrelor reversibly binds to the receptor. This means its effects wear off faster when you stop taking it.
Key differences from Effient:
Ticagrelor is recommended by guidelines alongside Prasugrel as a preferred P2Y12 inhibitor for ACS patients.
Cangrelor is an intravenous (IV) P2Y12 inhibitor used only in the hospital during PCI procedures. It's not a long-term oral alternative — it's used when a patient can't take an oral P2Y12 inhibitor at the time of the procedure. Your doctor may use it as a bridge before starting you on an oral medication like Effient, Clopidogrel, or Ticagrelor.
The best alternative depends on your individual situation. Factors your doctor will consider include:
For more on the cost of Effient and how to save, see our savings guide.
If you can't find or afford Effient, don't panic — but also don't skip doses. Talk to your cardiologist about your options. Clopidogrel (Plavix) and Ticagrelor (Brilinta) are both proven alternatives that can protect your heart after a stent procedure.
If availability is the issue rather than cost, try Medfinder to find a pharmacy near you that has Effient in stock. And for more information about this medication, check out our complete guide: What is Effient?
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.